"Pay to delay": How Big Pharma is paying off generic drug companies

Ironically, a law meant to help consumers is now hurting them:

The “pay to delay” deals are an anti-consumer twist on a law that was meant to help the public. The law was supposed to encourage generics to negotiate settlements that would bring them to market sooner, but the result has been a delayed market entry. Typically, the price of the first generic on the market is 20 percent lower than the brand-name price, and generic competition can reduce prices as much as 80 percent.

Increasingly, however, the industry’s idea of a settlement is to pay off the generics to kill the challenges. The Federal Trade Commission says Schering-Plough of Kenilworth paid $90 million to two generic companies positioned to market a cheaper version of a Schering blood pressure drug. Bristol Myers Squibb agreed to pay $40 million to a Canadian generic to delay a knockoff of the blockbuster blood thinner Plavix, a deal that eventually fell through and led to regime change at Bristol Myers Squibb.

(via PharmaGossip)

Related posts:

1. Drug companies responsible for generic side effects?
2. Do drug companies and the pharma industry deserve to be villains?
3. Pharmacies in bed with drug companies?
4. Paying doctors off to use generic medications
5. The booming generic medication business
6. Are generic drugs truly equivalent to brand name medications?
7. Districting viewers from drug risks

  Follow on Twitter   Subscribe